Ambenonium Chloride
The chloride salt form of ambenonium, a cholinesterase inhibitor used in the management of myasthenia gravis to increase acetylcholine availability at neuromuscular junctions. This formulation provides the same symptomatic relief of muscle weakness as the parent compound and has a longer duration of action than some other anticholinesterase agents.
Moleküler Ağırlık
608,5000 g/mol
TPSA
58,20 Ų
Etki Mekanizması
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl.[Cl-].[Cl-]
InChI
InChI=1S/C28H40Cl2N4O2.2ClH/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30;;/h9-16H,5-8,17-22H2,1-4H3;2*1H
Molecular Formula
C28H42Cl4N4O2
HBD / HBA
2 / 4
Döndürülebilir Bağlar
14
Ağır Atomlar
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The chloride salt form of ambenonium, a cholinesterase inhibitor used in the management of myasthenia gravis to increase acetylcholine availability at neuromuscular junctions. This formulation provides the same symptomatic relief of muscle weakness as the parent compound and has a longer duration of action than some other anticholinesterase agents.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Ambenonium Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200541. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 8288. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ambenonium-chloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ambenonium-chloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ambenonium-chloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ambenonium-chloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ambenonium-chloride"></drugfyi-drug>